PainChek Limited (ASX:PCK)
0.1250
+0.0100 (8.70%)
Sep 9, 2026, 3:43 PM AEST
PainChek Company Description
PainChek Limited engages in the development and commercialization of mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally.
The company provides PainChek, a clinically validated medical device that uses smartphone cameras for a facial scan then is analyzed using facial recognition AI technology to identify the presence of pain.
It serves individuals that are unable to communicate with their carers. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018.
PainChek Limited is based in Sydney, Australia.
PainChek Limited

| Country | Australia |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | Philip Daffas |
Contact Details
Address: 35 Lime Street Sydney, NSW 2000 Australia | |
| Phone | 61 4 2125 2123 |
| Website | painchek.com |
Stock Details
| Ticker Symbol | PCK |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000PCK6 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Iain McAdam | Chief Financial Officer |
| Andrew Hoggan | Chief Operating Officer |
| Prof. Jeff Hughes Ph.D. | Chief Scientific Officer |
| David Allsopp | GM and Head of Business Development of North America |
| Sasha Grant | Head of Growth for PainChek Infant App |
| Tandeep Gill | GM and Head of Business Development of UK&I |
| Natalie Sylvia Climo L.L.B. | Company Secretary |